Literature DB >> 2988745

Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus.

J W Clark, B H Hahn, D L Mann, F Wong-Staal, M Popovic, E Richardson, D M Strong, W S Lofters, W A Blattner, W N Gibbs.   

Abstract

The human T-cell leukemia virus type-I (HTLV-I) is a unique, exogenous, horizontally transmitted retrovirus which is T-cell tropic, and has been associated with a specific type of aggressive leukemia/lymphoma of mature T-cell origin. In a survey of lymphoid malignancies in Jamaica, antibodies to HTLV-I were also found in 6 of 17 patients with chronic lymphocytic leukemia (CLL), raising the possibility of an etiologic relationship. Further studies were undertaken on one of these patients to clarify the nature of the disease and possible virus relationship. Cell surface marker analysis of her peripheral blood cells documented that the majority of circulating lymphocytes were B-cells. DNA-cloned probe analysis with a complete HTLV-I proviral genome of these peripheral malignant B-cells, was negative for integrated virus. A T-cell line was established in culture from her peripheral blood. The presence of HTLV-I in the cultured T-cell line was established by the detection of expressed viral specific gag protein p-19 and proviral DNA. Thus, a B-cell lymphoid malignancy can occur in the presence of HTLV-I infected T-cells, suggesting the possibility of an indirect leukemogenic mechanism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988745     DOI: 10.1002/1097-0142(19850801)56:3<495::aid-cncr2820560314>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

2.  Human T lymphotropic virus type 1 in a seronegative B chronic lymphocytic leukemia patient.

Authors:  Pinhas Stark; Walter Bodemer; Horst Hannig; Jacob Luboshitz; Matityahu Shaklai; Batya Shohat
Journal:  Med Microbiol Immunol       Date:  2003-01-09       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.